RBBP6 and cancer: from molecular mechanisms to clinical implications.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Retinoblastoma binding protein 6 (RBBP6) is a 200 kDa E3 ubiquitin ligase.
• RBBP6 is overexpressed in multiple cancers, including lung, colorectal, breast, and hepatocellular cancers.
• Increased RBBP6 expression correlates with adverse clinicopathological parameters in several cancer types.

Purpose of the Study:

• To comprehensively review the molecular functions of RBBP6 in cancer development.
• To elucidate the mechanisms by which aberrant RBBP6 expression influences tumorigenesis and therapeutic response.
• To evaluate the prognostic and predictive significance of RBBP6 as a cancer biomarker and therapeutic target.

Main Methods:

• Literature review of studies on RBBP6 function and expression in various cancers.
• Analysis of RBBP6 interactions with substrates, signaling pathways (e.g., Jun N-terminal kinase), noncoding RNAs, and DNA damage proteins.
• Evaluation of clinical data linking RBBP6 expression to clinicopathological parameters and patient outcomes.

Main Results:

• RBBP6 promotes cancer progression through interactions that enhance cell proliferation, stemness, cell cycle progression, and metastasis.
• Aberrant RBBP6 expression is linked to malignant progression and specific clinicopathological features across diverse tumor types.
• RBBP6's multifaceted roles suggest its significance in cancer development and response to treatment.

Conclusions:

• RBBP6 is a key molecular player in tumorigenesis across multiple cancer types.
• Understanding RBBP6's mechanisms offers insights into cancer development and potential therapeutic strategies.
• RBBP6 holds promise as a prognostic biomarker and a molecular target for cancer therapy.